Table 2.

Changes in laboratory measures on voxelotor

	Wk 4	Wk 8	Wk 12
dHb, g/dL	1.2 (0.4-1.5)∗	0.9 (0.4-1.2)∗	0.8 (0.2-1.4)∗
dRetic, %	−2.8 (−3.3 to −0.7)†	−1.2 (−4.2 to 0.1)†	−1.4 (−2.5 to −0.4)†
dWBC, 1000/μL	−1.0 (−1.2 to −0.2)†	0.4 (−2.0 to 1.4)	−0.8 (−1.6 to −0.1)∗
dLDH, U/L	—	—	27 (−10 to 64)
dBilirubin, μmol/L	—	—	−0.9 (−1.3 to −0.5)‡

Data are reported as median (IQR). P values were obtained from a 2-sided paired Wilcoxon signed-rank test.

dBilirubin, changes from pretreatment levels in bilirubin at 4, 8, and 12 wk of treatment; dHb, changes from pretreatment levels in Hb at 4, 8, and 12 wk of treatment; dLDH, changes from pretreatment levels in LDH at 4, 8, and 12 wk of treatment; dRetic, changes from pretreatment levels in reticulocytes at 4, 8, and 12 wk of treatment; dWBC, changes from pretreatment levels in white blood cell count at 4, 8, and 12 wk of treatment.

^∗P < .05.

^†P < .01.

^‡P < .005.